SCHEMBL8440174

SCHEMBL8440174

COC(=O)C1=C(C)N(C)C(C)=C(C(C)=O)C1c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.61
HSD17B10 Q99714 2/20 0.61
NPSR1 Q6W5P4 4/20 0.60
HPGD P15428 2/20 0.60
KDM4E B2RXH2 1/20 0.60
ADORA3 P0DMS8 1/20 0.56
HTT P42858 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
LMNA P02545 2/20 0.50
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
ADRA2A P08913 3/20 0.45
ADRA2B P18089 3/20 0.45
ADRA2C P18825 3/20 0.45
ADRA1D P25100 3/20 0.45
ADRA1A P35348 3/20 0.45
ADRA1B P35368 3/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8871052 0.86 TSHR (0.61) TSHRHSD17B10NPSR1ADORA3MEN1
SCHEMBL8437356 0.83 ADORA3 (0.42) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL8441842 0.82 TSHR (0.68) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL8345995 0.82 NPSR1 (0.89) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL11864469 0.82 NPSR1 (0.56) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL11863359 0.81 TSHR (0.67) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL9064391 0.81 ADORA3 (0.78) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL16189736 0.80 TSHR (0.66) TSHRHSD17B10NPSR1ADORA3MEN1
SCHEMBL14987375 0.78 TSHR (0.79) TSHRHSD17B10NPSR1HPGDKDM4E
SCHEMBL7160123 0.78 ADORA3 (0.85) TSHRHSD17B10NPSR1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0717036-B1 Use of 5-acyl-1,4-dihydropyridines for the treatment of diseases of the CNS BAYER AG (DE) 1999-03-17 EP claimed
US-5646166-A POTASSIUM CHANNEL MODULATORS, TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 1997-07-08 US claimed